Who are Stelazine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pramipexole (Mirapex), Prolixin Decanoate, Thioridazine-2-Sulfoxide, Moditen Enanthate, Prolixin, Trilafon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trifluoperazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Stelazine — Competitive Intelligence Brief

Stelazine (TRIFLUOPERAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phenothiazine. Area: Neuroscience.

marketed Phenothiazine D(3) dopamine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Stelazine (TRIFLUOPERAZINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Stelazine TARGET	TRIFLUOPERAZINE		marketed	Phenothiazine	D(3) dopamine receptor	1959-01-01
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
Prolixin Decanoate	FLUPHENAZINE DECANOATE	Bristol-Myers Squibb	marketed	Phenothiazine	D(2) dopamine receptor	1972-01-01
Thioridazine-2-Sulfoxide	MESORIDAZINE		marketed	Phenothiazine	Histamine H1 receptor	1970-01-01
Moditen Enanthate	FLUPHENAZINE ENANTHATE	Bristol-Myers Squibb	marketed	Phenothiazine	D(3) dopamine receptor	1967-01-01
Prolixin	FLUPHENAZINE		marketed	Phenothiazine	D(3) dopamine receptor	1959-01-01
Trilafon	PERPHENAZINE		marketed	Phenothiazine [EPC]	D(3) dopamine receptor	1957-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phenothiazine class)

· 3 drugs in this class
Bristol-Myers Squibb · 2 drugs in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Stelazine — Competitive Intelligence Brief. https://druglandscape.com/ci/trifluoperazine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab